Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 607
- Registration Number
- NCT01734785
- Locations
- 🇪🇸
1275.9.34011 Boehringer Ingelheim Investigational Site, A Coruña, Spain
🇪🇸1275.9.34009 Boehringer Ingelheim Investigational Site, Alicante, Spain
🇳🇴1275.9.47006 Boehringer Ingelheim Investigational Site, Svelvik, Norway
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 470
- Registration Number
- NCT01732796
- Locations
- 🇺🇸
1241.20.00002 Boehringer Ingelheim Investigational Site, Chevy Chase, Maryland, United States
🇺🇸1241.20.00012 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇨🇦1241.20.01008 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 496
- Registration Number
- NCT01728324
- Locations
- 🇺🇸
1241.36.00005 Boehringer Ingelheim Investigational Site, Bakersfield, California, United States
🇺🇸1241.36.00002 Boehringer Ingelheim Investigational Site, Arlington, Texas, United States
🇦🇺1241.36.61002 Boehringer Ingelheim Investigational Site, Herston, Queensland, Australia
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
- First Posted Date
- 2012-11-14
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 689
- Registration Number
- NCT01726270
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, Richmond, Virginia, United States
Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4340
- Registration Number
- NCT01721837
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 729, Duisburg, Germany
🇩🇪Boehringer Ingelheim Investigational Site 1106, Eckernfoerde, Germany
🇩🇪Boehringer Ingelheim Investigational Site 736, Duisburg, Germany
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 666
- Registration Number
- NCT01721876
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇫🇷HOP Côte de Nacre, Caen, France
🇫🇷HOP Haut-Lévêque, Pessac, France
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2Hyperglycemia
- Interventions
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1413
- Registration Number
- NCT01719003
- Locations
- 🇺🇸
1276.1.10010 Boehringer Ingelheim Investigational Site, Glendale, Arizona, United States
🇺🇸1276.1.10008 Boehringer Ingelheim Investigational Site, Greer, South Carolina, United States
🇬🇹1276.1.50005 Boehringer Ingelheim Investigational Site, Guatemala, Guatemala
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT01711853
- Locations
- 🇳🇱
1160.166.31001 Boehringer Ingelheim Investigational Site, Leiden, Netherlands
Nonivamide/Nicoboxil Ointment in Acute Low Back Pain
- Conditions
- Acute Low Back Pain
- Interventions
- Drug: placebo matching nonivamide + nicoboxil
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 805
- Registration Number
- NCT01708915
- Locations
- 🇩🇪
69.52.49032 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪69.52.49024 Boehringer Ingelheim Investigational Site, Essen, Germany
🇩🇪69.52.49039 Boehringer Ingelheim Investigational Site, Fürth, Germany
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: linagliptin2.5mg/metformin500mgDrug: linagliptin2.5mg/metformin1000mg
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 876
- Registration Number
- NCT01708902
- Locations
- 🇨🇳
1288.18.86010 Boehringer Ingelheim Investigational Site, Guangzhou, China
🇨🇳1288.18.86039 Boehringer Ingelheim Investigational Site, Nanchang, China
🇨🇳1288.18.86024 Boehringer Ingelheim Investigational Site, Xi'An, China